Check for updates

OPEN ACCESS

EDITED BY Bo Zhai, Shanghai Jiao Tong University, China

REVIEWED BY Chen Li, Free University of Berlin, Germany Jing Zhang, University of South Dakota, United States

CORRESPONDENCE Dalong Wei gxweidalong@ymcn.edu.cn Honguan Lu 365485696@qq.com Yu Cao 2692327139@qq.com

[†]These authors have contributed equally to this work

RECEIVED 17 February 2024 ACCEPTED 22 March 2024 PUBLISHED 10 April 2024

CITATION

Rong D, Su Y, Jia D, Zeng Z, Yang Y, Wei D, Lu H and Cao Y (2024) Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM. *Front. Immunol.* 15:1387316. doi: 10.3389/fimmu.2024.1387316

COPYRIGHT

© 2024 Rong, Su, Jia, Zeng, Yang, Wei, Lu and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM

Dongyun Rong^{1†}, Yushen Su^{1†}, Dechao Jia^{1†}, Zhirui Zeng^{2,3†}, Yan Yang⁴, Dalong Wei^{5,6*}, Honguan Lu^{1*} and Yu Cao^{1*}

¹Clinical Medical School, Guizhou Medical University, Guiyang, Guizhou, China, ²Department of anorectal surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China, ³School of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China, ⁴Department of Internal Medicine, The Third Affiliated Hospital of Guizhou Medical University, Duyun, Guizhou, China, ⁵Department of Burns, Plastic Surgery and Wound Repair, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China, ⁶Key Laboratory of Tumor Molecular Pathology of Baise, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China

Background: Skin Cutaneous Melanoma (SKCM) incidence is continually increasing, with chemotherapy and immunotherapy being among the most common cancer treatment modalities. This study aims to identify novel biomarkers for chemotherapy and immunotherapy response in SKCM and explore their association with oxidative stress.

Methods: Utilizing TCGA-SKCM RNA-seq data, we employed Weighted Gene Coexpression Network Analysis (WGCNA) and Protein-Protein Interaction (PPI) networks to identify six core genes. Gene co-expression analysis and immunerelated analysis were conducted, and specific markers associated with oxidative stress were identified using Gene Set Variation Analysis (GSVA). Single-cell analysis revealed the expression patterns of Oxidative Stress-Associated Genes (OSAG) in the tumor microenvironment. TIDE analysis was employed to explore the association between immune therapy response and OSAG, while CIBERSORT was used to analyze the tumor immune microenvironment. The BEST database demonstrated the impact of the Oxidative Stress signaling pathway on chemotherapy drug resistance. Immunohistochemical staining and ROC curve evaluation were performed to assess the protein expression levels of core genes in SKCM and normal samples, with survival analysis utilized to determine their diagnostic value.

Results: We identified six central genes associated with SKCM metastasis, among which the expression of DSC2 and DSC3 involved in the oxidative stress pathway was closely related to immune cell infiltration. DSC2 influenced drug resistance in SKMC patients. Furthermore, downregulation of DSC2 and DSC3 expression enhanced the response of SKCM patients to immunotherapy.

Conclusion: This study identified two Oxidative Stress-Associated genes as novel biomarkers for SKCM. Additionally, targeting the oxidative stress pathway may serve as a new strategy in clinical practice to enhance SKCM chemotherapy and sensitivity.

KEYWORDS

SKCM, oxidative stress network, immunotherapy response, drug resistance, immune

1 Introduction

Melanoma originates from neuroectodermal melaninproducing cells, known as SKCM, distributed across various tissues, with predilection for skin and mucous membranes. The rising incidence of melanoma is attributed to factors like UV exposure, oxidative stress, DNA damage, and mutations, culminating in its genesis (1). SKCM, characterized by its high incidence, metastasis, and mortality rates, represents the most invasive malignancy of skin melanocytes. Its poor prognosis stems from early metastasis and challenging early-stage diagnosis (2). Given its significant morbidity and economic burden, early detection and stratification of novel biomarkers are imperative for enhancing SKCM management.

Notably, various factors contribute significantly to SKCM development, warranting the identification of biomarkers. For instance, Wang et al. correlated SRGN expression with SKCM and SKCM-metastasis patient survival (3). Zhang et al. associated lower GBP2 expression with reduced immune cell infiltration and poorer SKCM prognosis (4). Additionally, B cell characteristics play pivotal prognostic (5, 6), and predictive roles in SKCM, shaping its immunobiology and potential immunogenomics features (7).

Oxidative stress, implicated in aging, inflammation, and chronic diseases, results from the imbalance between reactive oxygen and nitrogen species and a compromised antioxidant defense system. Studies by Elena Piskounova et al. revealed that oxidative stress inhibits distant metastasis in human melanoma cells (8, 9). Moreover, oxidative stress is linked to various cancers, with drugs like doxorubicin modulating oxidative stress to improve survival (10). Intracellular oxidative stress amplification is explored as a synergistic cascade cancer therapy strategy (11). Recent research developed an oxidative stress-related prognostic model for SKCM, offering new insights for melanoma analysis (12).

Challenges in malignant melanoma diagnosis and treatment include the development of primary or secondary drug resistance in over half of patients, rendering existing treatments ineffective. Addressing this necessitates identifying new molecular therapeutic targets to enhance SKCM patient management. Thus, this article aims to identify and evaluate novel potential biomarkers, offering valuable insights for further exploration.

2 Materials and methods

2.1 Data collection and processing

Clinical specimens were provided by Guizhou Medical University Affiliated Hospital (Guiyang, China), comprising 92 pairs of tumor and adjacent samples (1-2 cm from tumor tissue). These samples encompassed 24 trunk subtype samples and 68 other subtype samples. Approval for this study was obtained from the Human Characteristics Ethics Committee of Guizhou Medical University, and the principles of the Helsinki Declaration were strictly followed. Informed consent was also obtained from patients providing samples.

Transcriptomic data and related clinical information were sourced from the TCGA database (https://portal.gdc.cancer.gov/ projects/TCGA-SKCM). The RNA-sequencing dataset encompasses 472 samples, including 78 samples from Trunk Cutaneous Melanoma (TCM) and 394 samples from other melanoma subtypes. A threshold of 140, post-normalization, was applied to identify outliers using the hierarchical clustering algorithm. The cut-off for FPKM was established at 0.5 to exclude genes with low expression levels. A threshold of 0.5 was set during gene selection. Following merge and batch normalization, differential expression genes (DEGs) are identified using "sva" R package (13–15). Moreover, DEGs were discerned between tumor and normal tissues using a cut-off value of [Log2 fold-change (FC)] > 0.5 and an adjusted *P*-value < 0.05 (16).

2.2 Gene co-expression network construction and identification of crucial clinical modules

Genes were analyzed for the construction of a scale-free network via the "WGCNA" methodology (17, 18). This expression network, predicated on weighted gene co-expression data, was established utilizing the top quartile of genes exhibiting the highest variance. Initially, an expression data-derived similarity matrix was generated to compute the absolute values of Pearson correlation coefficients between gene pairs. Subsequently, this similarity matrix was transformed into an adjacency matrix, with the application of a soft threshold that accentuated strong connections while diminishing the significance of weaker

10.3389/fimmu.2024.1387316

correlations within the matrix. This adjacency matrix was further converted into a topological overlap matrix (TOM), designed to more accurately depict the strength of relationships and the degree of connectivity among genes within the dataset. Serving as a measure for assessing network connectivity among genes, TOM was employed as an input for hierarchical clustering analysis. The "DynamicTreeCut" algorithm, utilized within the "WGCNA" R package, facilitated the identification of network modules (19). Following module identification, gene significance (GS) was evaluated, correlating these genes with other biological information. The higher the GS value, the more substantial the prognostic relevance for patients. Hence, an analysis employing Pearson's correlation coefficient was conducted to ascertain the correlation between identified modules and clinical features, including patient age and cancer stage. Through this approach, "WGCNA" aids in elucidating the connections between gene expression patterns and clinical characteristics, offering vital insights for the discovery of biomarkers and the formulation of therapeutic strategies for disease management.

2.3 GO and KEGG enrichment

GO and KEGG enrichment analyses were conducted using the R package "clusterProfiler" to explore pivotal modules, with P < 0.05 defined as significant enrichment (20). These analyses aimed at identifying potential signaling pathways, elucidating the biological processes and pathways crucial in the occurrence and progression of melanoma (21).

2.4 Construction of PPI network and gene co-expression analysis

PPI network was constructed using the online STRING database (https://string-db.org/). During network construction, disconnected nodes were removed to ensure network connectivity. Subsequently, the network graph of key modules was created using Cytoscape 3.72, revealing crucial interactions by identifying the top 30 ranked genes. Each node in the PPI network represents a protein encoded by a gene, while edges depict interactions between two proteins. To explore the potential of DSC2 and DSC3 as novel targets for regulatory intervention, an analysis was conducted to identify genes that show co-expression with these markers. This analysis highlighted twelve genes exhibiting the highest co-expression coefficients with DSC2 and DSC3. The findings, represented in a circular graph, underscore the importance of further investigation into these associated genes, suggesting they warrant closer scrutiny.

2.5 Survival analysis

Survival analysis was conducted using the "survival" and "survminer" packages in R language (22). Initially, patients were

stratified into high and low expression groups based on the median gene expression levels, and the association between these gene expression levels and prognosis was determined using the Logrank test.

2.6 Single-cell analysis combined with CIBERSORT examination of immune infiltration

Subsequently, exploration of subpopulation clustering in SKCM at the single-cell level was carried out utilizing the TISCH2 singlecell database (23). Briefly, the "Seurat" package is employed for scrutinizing scRNA-seq data of SKCM (18). Initially, following the exclusion of cells expressing fewer than 250 or exceeding 6000 genes, a logarithmic normalization is performed on gene expression. Subsequently, employing the functions "FindNeighbors" and "FindClusters", individual cells are clustered into distinct subgroups. To further elucidate the roles of DSC2 and DSC3 in immune infiltration, the "CIBERSORT" algorithm was employed to calculate immune infiltration scores in each sample (24). Samples were dichotomized based on the median gene expression levels, comparing the infiltration of various types of immune cells between these two groups and assessing DSC2 and DSC3 respectively. The correlation analysis between gene expression and immune cell infiltration was visualized using the "ggplot2" package, including box plots and correlation scatter plots. Finally, the correlation between genes and immune checkpoints was analyzed using the "corrplot" package and visualized through heat maps. Furthermore, specific gene associations with immune checkpoint genes were evaluated.

2.7 Evaluation of immunotherapy response and chemotherapy resistance

In recent years, immunotherapy has emerged as a promising anti-tumor strategy (25), demonstrating favorable anti-tumor effects in SKCM treatment. Hence, further investigation into the role of oxidative stress-related genes in SKCM immunotherapy was conducted. The association between immunotherapy response and oxidative stress-related genes was explored using TIDE analysis. Additionally, the BEST database illustrated the impact of oxidative stress signaling pathways on chemotherapy drug resistance. Immunohistochemical staining and ROC curve analysis were employed to evaluate the protein expression levels of core genes in SKCM and normal samples, and their diagnostic value was determined through survival analysis (26).

2.8 Gene set variation analysis

GSVA is a non-parametric unsupervised analytical method used to assess the enrichment of gene sets in transcriptome data (27). The score of oxidative stress were determined by the "ssGSEA" using "GSVA" R package, and the certain signatures that respond to oxidative stress were obtained from database (http:// www.informatics.jax.org/vocab/gene_ontology/GO:0006979). This method transforms gene expression data into an expression matrix characterized by a specific set of genes (28). Besides, Pearson correlation analysis was conducted to validate the correlation between hub genes and oxidative stress scores. Through this process, we could assess association between screened genes and oxidative stress.

2.9 Immunohistochemistry experiment

In an ambient laboratory environment, tissues were subjected to a 4% Paraformaldehyde fixation process. Subsequently, these specimens were encased within paraffin blocks and dissected into sections of 4 µm in thickness. The process of removing paraffin was conducted utilizing xylene at a temperature of 60°C, succeeded by a graded rehydration sequence employing ethanol concentrations of 100%, 80%, 60%, and 40%. To inhibit the intrinsic peroxidase reactions present in the samples, 3% H2O2 was utilized, while sodium served the purpose of facilitating antigen retrieval. Following a 16-hour incubation period at 4°C in a medium containing 5% bovine serum albumin, the sections underwent a further incubation with an array of primary antibodies (Santa Cruz, CA, USA), specifically (DSC2; 1:200), (DSC3; 1:200), (DSG1; 1:200), (KRT6B; 1:200), (PKP1; 1:200), and (PKP3; 1:400). Subsequent to this, for a duration of 2 hours at an ambient temperature, the sections were exposed to secondary antibodies targeted against mouse and rabbit immunoglobulins. Visual documentation of the samples was achieved using a high-resolution light microscopy technique, employing magnification levels of x200 and x400. Following this, a staining protocol involving 3,3' diaminobenzidine and hematoxylin was applied for a minute at ambient temperature. The evaluation of the staining intensity for the genes of interest was performed, with scores assigned as follows: 0 indicating no staining, 1 for weak positivity, 2 for moderate positivity, and 3 for strong positivity, facilitating the quantification of protein expression. The Image Pro Plus software was employed to determine the scoring based on the proportion of positively stained cells, with a scoring rubric of 0-2 for low expression, 3-4 for moderate expression, and 5-6 denoting high expression. P-value < 0.05 was interpreted as indicative of a statistically significant variance.

2.10 Statistical analysis

All statistical analyses were conducted using packages in the R programming language (version 3.6.3). Prior to statistical analysis, normality tests were performed to determine the appropriate statistical methods. Analysis of normal and non-normal data was conducted using unpaired Student's t-test and Wilcoxon test, respectively (29). Pearson method was employed for correlation analysis, with P < 0.05 considered statistically significant. * P < 0.05, ** P < 0.01, **** P < 0.001.

3 Results

3.1 Construction of WGCNA coexpression network

Upon downloading and integrating expression data along with clinical data, no aberrant samples were identified through the sample dendrogram, and most clinical features were documented (Figure 1A). Subsequently, the WGCNA network was constructed using the gene expression profile after filtering out low-expressed genes. The WGCNA algorithm was applied to construct co-expression networks and modules for 472 samples from TCGA. We selected the top 25% mutated genes from the TCGA-SKCM cohort and performed clustering analysis using the 'WGCNA' R package. With a soft threshold β set to 11, the scale independence of the topological network exceeded 0.85, and the average connectivity approached 0 (Figures 1B, C). Therefore, setting the soft threshold to β =11 satisfied the scale-free topology criterion, with $R^2 = 0.88$ for the TOM (Figure 1D). The dynamic tree cutting algorithm based on TOM was employed to cluster all selected genes, resulting in the division of the tree into 12 modules (Figure 1E), each labeled with distinct colors.

3.2 Identification of key modules and central genes associated with clinical features

Subsequently, we summarized the co-expression of feature genes and calculated the correlation between feature genes and clinical characteristics. Pathological diagnosis typically includes information on pathological stages M, N, and T at the time of diagnosis. Each module consists of distinct gene clusters, marked in an overlapping heatmap with different colors; red indicating positive correlation and green indicating negative correlation (Figure 2A). Among the co-expression modules and features we analyzed, we observed that the yellow module is most closely related to pathological stage M (R=0.43, P=1e-04); additionally, this module is positively correlated with age (R=0.25, P < 0.05) (Figure 2B). Therefore, we consider the yellow module containing 520 genes as a critical gene module and employ it for further analysis (Figure 2C).

3.3 Analysis of KEGG pathways and GO enrichment

To elucidate the functional mechanisms of the yellow module, we conducted enrichment analyses of GO terms and KEGG pathways. In this study, we initially examined biological processes (BP), molecular functions (MF), and cellular components (CC) to identify the most enriched GO pathways. The results revealed that, in terms of biological processes, these genes are primarily involved in epidermal development, keratinocyte differentiation, and keratinization processes. Regarding cellular components, the main enrichment was observed in cornified envelope, extracellular region,



FIGURE 1

Analysis of SKCM weighted gene co-expression networks by WGCNA. (A) Dendrogram illustrating samples of SKCM along with clinical patient characteristics. (B) Evaluation of scale independence fit indexes through soft thresholding power analysis. (C) Soft thresholding power analysis depicting mean connectivity. (D) Demonstration of topology with scale-free scaling at β =11. (E) Identification of 12 gene co-expression modules utilizing a dissimilarity measure.



and extracellular region part. Molecular function analysis indicated that these genes are predominantly enriched in epidermal structural components (Figure 3A). Subsequently, based on the enrichment results of KEGG pathways, we identified pathways closely associated with tumorigenesis, including central carbon metabolism, cell adhesion molecules, junctional protein binding, and melanogenesis, providing important clues for understanding the functional mechanisms of genes within the yellow module (Figures 3B, C).

3.4 Relationship between central genes and oxidative stress characteristics

To explore the interrelations among genes and identify central genes, an initial analysis was conducted on genes within the yellow module, followed by visualization using STRING. After eliminating unconnected nodes, a PPI network was obtained (Figure 4A). Subsequently, employing 'Cytoscape', topological parameters for all nodes were computed, and the six highest-ranking node genes were identified as pivotal for subsequent analyses (Figure 4B). To investigate the association between central genes (DSC2, DSC3, DSG1, KRT6B, PKP1, and PKP3) and the response to oxidative stress, we employed GSVA to compute the oxidative stress scores for each sample. Pearson correlation analysis revealed a significant correlation between oxidative stress scores and DSC2 (R=0.45; P < 0.001) as well as DSC3 (R=0.094; P < 0.05), whereas other genes showed no involvement in the oxidative stress response (Figure 4C).

This underscores the need for further exploration into the relationship between oxidative stress and DSC2, DSC3.

3.5 Gene co-expression analysis and survival analysis

Through correlation analysis, we identified a set of 12 genes highly correlated with both DSC2 and DSC3, and delved into the interrelationships among them. Circular diagrams were presented for DSC2 (Figure 4D) and DSC3 (Figure 4E) separately to illustrate their associations. KM survival analysis was conducted on these selected central genes, revealing a significant association with the prognosis of SKCM patients (P < 0.05). As the expression levels of DSC2, DSC3, DSG1, KRT6B, PKP1, and PKP3 increased, the overall survival time of trunk subtype melanoma patients significantly decreased (Figure 5).

3.6 Immune infiltration

Immunohistochemical analysis revealed heightened infiltration levels of NK cells, with significant differences observed between groups with varying DSC2 expression levels. Likewise, significant disparities in dendritic cell activation and infiltration were evident between the two DSC3 expression level groups (Figure 6A). Furthermore, a positive correlation was identified between DSC2





expression and activation of CD4 memory T cells, dendritic cells, mast cells, and neutrophil infiltration. Conversely, DSC2 expression exhibited a negative correlation with regulatory T cells and activated NK cell infiltration (Figure 6B). Additionally, DSC3 expression showed a positive correlation with dendritic cell activation and neutrophil infiltration. Figure 6C depicts the association between DSC2 and DSC3 and highly correlated immune checkpoint genes.

3.7 Analysis of GSVA

Subsequently, we compared the functional pathways associated with different oxidative stress scores in melanoma. Utilizing GSVA, we assessed the oxidative stress-related signaling pathways in melanoma and further explored them based on KEGG and GO datasets. Enriched genes, signaling pathways, and functions were



highlighted using heatmap plots. In the KEGG analysis, we investigated the top 20 associated signaling pathways such as the MAPK signaling pathway, JAK STAT signaling pathway (Figure 7A). Additionally, GO analysis revealed significant differential functional pathways between the two oxidative stress groups, presenting the top 20 signals in Figure 7B, including muscle cell proliferation, growth factor receptor binding.

3.8 Single-cell analysis reveals the expression patterns of oxidative stress in subpopulations of SKMC cells

We identified a close association between DSC2 and DSC3 with oxidative stress processes. Further investigation demonstrated a positive correlation between the expression of DSC2 and DSC3 and the infiltration of activated dendritic cells and neutrophils, while showing a negative correlation with memory B cells (Figures 8A, B). Subsequently, we delved deeper into the expression patterns of DSC2 and DSC3 at the single-cell level (Figure 8C). Remarkably, the average expression level of DSC2 was highest in monocytes, followed by pDCs (Figures 8D, E). Interestingly, DSC3 was predominantly enriched in NK cells, CD8 T cells, and CD4 T cells (Figures 8F, G), indicating distinct spatial distributions of these two oxidative stress molecules.

3.9 Impact of DSC2 on immunotherapy response and chemotherapy resistance

Immunotherapy, as a prominently featured anticancer strategy in recent years, has demonstrated significant efficacy in the treatment of SKCM. However, some patients exhibit insensitivity or even develop resistance to immunotherapy. Thus, we further investigated the role of oxidative stress-related genes in SKCM immunotherapy. It was observed that patients with high expression levels of DSC2 and DSC3 were more sensitive to immunotherapy (Figures 9A, B), possibly due to infiltration by macrophages and CD8 T cells (Figures 9C, D). Additionally, DSC2 could serve as an effective predictive biomarker for immunotherapy response in SKCM patients (Figure 10A). Intriguingly, SKCM patients with high expression of DSC2 exhibited poorer prognosis following Anti-PD-1/PD-L1 therapy compared to those with lower DSC2 expression (Figure 10B), which may be attributed to the protumorigenic characteristics of DSC2. Furthermore, chemotherapy, as a crucial component of anticancer therapy, often fails ultimately due to the development of resistance. Therefore, we further investigated the expression of DSC2 in drug resistance. Results indicated that SKCM patients with high expression of DSC2 were more prone to developing resistance to Apitolisib, Motesanib, and Amuvatinib (Figure 11), suggesting DSC2 as one of the targeted strategies to enhance chemotherapy sensitivity.

3.10 Immunohistochemistry reveals distinct expression patterns of core proteins across trunk subtypes

Given the lack of expression profiles for adjacent normal tissues within the TCGA-SKCM cohort, a total of 92 SKCM samples were obtained, comprising both tumor and adjacent normal tissues. Differential expression analysis of these core proteins was subsequently performed through immunohistochemistry experiments (Figures 12A, 13A). The results indicate that in trunk subtype melanomas, the protein expression levels of DSC2, DSC3,



DSG1, KRT6B, PKP1, and PKP3 are significantly higher than those in adjacent normal samples (Figures 12B, C), suggesting the crucial roles of these central genes in SKCM progression. However, in other subtype melanoma patients, only DSG1 and PKP1 exhibit significantly elevated protein expression levels compared to adjacent normal samples, with no observed differences in other genes between tumor and adjacent normal samples (Figures 13B, C).

4 Discussion

SKCM continues to challenge oncology, with its heterogeneity in clinicopathological and cytological features complicating

prognosis and treatment (30). Recent advancements have highlighted the role of oxidative stress in melanoma progression, metastasis, and resistance to therapy (31). This study leveraged high-throughput data to unravel the complex interplay between hub genes, oxidative stress, and the immune landscape in SKCM, offering novel insights into its pathogenesis and potential therapeutic targets.

Our analysis, grounded in WGCNA and PPI networks, identified six genes (DSC2, DSC3, DSG1, KRT6B, PKP1, PKP3) with pivotal roles in melanoma's oxidative stress response and immune infiltration (32, 33). Particularly, DSC2 and DSC3's association with oxidative stress underscores their potential as biomarkers for SKCM prognosis and therapy response (34). The



FIGURE 7

GSVA analysis. (A) GSVA depicting the relationship between oxidative stress and KEGG pathways. (B) GSVA illustrating the relationship between oxidative stress and GO pathways.



FIGURE 8

Expression patterns of oxidative stress pathways in single-cell subtypes. (A, B) Correlation between DSC2, DSC3, and immune cell infiltration. (C) Subtypes of single cells in SKCM patients. (D, E) Expression patterns of DSC2 and DSC3 in subtypes of SKCM patient cells. (F, G) Expression patterns of DSC3 in subtypes of SKCM patient cells.



significant variation in their expression between melanoma subtypes and adjacent normal tissues suggests these genes influence melanoma development, possibly by modulating cell adhesion pathways crucial for tumor metastasis. SKCM can occur on various parts of the human body, indicating potential significant heterogeneity among them. Emi et al., using "anatomical location" as a variable, classified melanoma patients into three categories: limbs, trunk, and head/neck. They discovered that melanomas at different anatomical locations possess distinct risk factors (35). Epidemiological studies have shown that most melanomas are located on the lower limbs, followed by the trunk, with melanomas of the head and neck and those with unspecified anatomical locations having the poorest survival rates (36). Trunk SKCMs tend to have less sun exposure compared to facial SKCMs, and studies have confirmed that anti-PD-1 immunotherapy is particularly recommended for melanomas originating from areas of chronic sun exposure (37). This underscores the necessity of conducting separate research on trunk-SKCM and non-trunk SKCM. Our findings indicate that trunk-SKCMs, compared to normal tissue, exhibit higher activation of oxidative stress



pathways, such as DSC2 and DSC3. Conversely, these differences are not significantly observed in other subtypes of SKCM.

In the progression and onset of cancer, the immune system assumes a pivotal role (38, 39), rendering immunotherapy research a promising therapeutic avenue (40, 41). Immune infiltration analysis revealed a significant correlation between the expression levels of DSC2, DSC3, and the infiltration of various immune cells, highlighting the intricate relationship between the tumor microenvironment and melanoma progression (42). High DSC2 expression correlated with increased infiltration of CD4 memory activated T cells, dendritic cells, mast cells, and neutrophils, while negatively correlating with regulatory T cells and activated NK cells. Similar to our study, Li et al. found that the proportion of CD4+ memory-activated T cells is higher in metastatic melanoma. These T cells may become exhausted due to excessive activation, exhibiting tumor immune suppression (17, 43). Early infiltration of mast cells is found in various human and animal tumors, particularly malignant melanoma (44). Within the tumor, mast cells interact with infiltrating immune cells, tumor cells, and ECM through direct cell-cell interactions or by releasing various mediators capable of



reshaping the TME (44, 45). Mast cells can facilitate tumor angiogenesis and tumor cell proliferation by releasing proangiogenic and pro-tumorigenic factors (46–48). Similarly, DSC3's expression positively correlated with dendritic cells and neutrophil infiltration (49, 50). Neutrophils play a crucial role in tumor development by promoting tumor cell proliferation, invasion, and metastasis (51, 52). These findings suggest that DSC2 and DSC3 not only contribute to the oxidative stress response but also play a central role in modulating the immune landscape of SKCM.

A multitude of variables exert influence on the progression of tumors (53–56), encompassing proliferation, metastasis (57), and resistance to treatment (58). The role of oxidative stress in tumor immune infiltration represents a focal point of contemporary research interest (59). Excessive oxidative stress can detrimentally impact the immune system. For instance, elevated levels of oxidative stress may precipitate apoptosis or impair functionality in immune cells, thereby diminishing the efficacy of immune infiltration (60–

62). Moreover, oxidative stress may facilitate the proliferation and functional enhancement of immune suppressive cells within the tumor microenvironment, such as TAMs, further inhibiting the immune cells' action against tumors (63, 64). Currently, immunotherapy is recognized as an effective treatment strategy for various cancers (65). Yu et al. have delineated the interactions between oxidative stress and the TME suggesting the potential of oxidative stress to augment immunotherapy (66). Our findings indicate that high expression of DSC2 and DSC3 is indicative of an improved immune response (Figures 9A, B). However, this is inversely related to survival in patients undergoing anti-PD-1/PD-L1 therapy, while positively correlated with survival benefits in patients treated with anti-CTLA-4 therapy (Figure 10B). This suggests that the oxidative stress pathway may influence the expression patterns of CTLA-4.

Moreover, our study delves into the impact of these genes on drug resistance and response to immunotherapy (67, 68). The



Expression patterns of core proteins in trunk-subtype. (A) Heatmap illustrating expression patterns. (B, C) Immunohistochemistry confirming high expression of DSC2, DSC3, DSG1, KRT6B, PKP1, and PKP3 in trunk-subtype SKCM. **P < 0.01.



FIGURE 13

Expression patterns of core proteins in other-subtype. (A) Heatmap depicting expression patterns. (B, C) Immunohistochemistry confirming the expression of DSC2, DSC3, DSG1 in other-subtype SKCM. *P < 0.05, **P < 0.01.

expression of DSC2, in particular, was found to influence SKCM patients' sensitivity to immunotherapy and chemotherapy drugs, pointing toward its potential as a predictive biomarker for treatment response (69). This is critical, considering the increasing application of immunotherapy in SKCM treatment and the challenge of overcoming drug resistance. It is worth noting that Sven et al. found that knockdown of DSC2 in mice resulted in damaged colonic mucosal repair, which was associated with decreased levels of integrins β 1 and β 4 (70, 71). Additionally, Vite et al. observed that low expression of DSC2 was associated with ventricular developmental abnormalities (72). Therefore, in future studies targeting DSC2 for the treatment of SKCM, it is necessary to consider its role in protecting myocardium and intestinal mucosa function.

However, this study is not without limitations. The reliance on TCGA data, with its scarce normal samples, introduces potential biases (73), and the six hub genes identified may not cover all genes associated with SKCM survival (74). Furthermore, our conclusions are primarily drawn from bioinformatic analyses and require validation through experimental studies and prospective cohorts to confirm these genes' roles in SKCM pathogenesis and their therapeutic potential.

In conclusion, this investigation enriches our understanding of melanoma's molecular underpinnings, emphasizing the significance of oxidative stress and immune infiltration in its progression. The identified hub genes offer promising directions for future research into targeted therapies for SKCM, aiming to improve patient prognosis and combat resistance to existing treatments. Further experimental validation and clinical trials are essential to translate these findings into clinical applications, potentially revolutionizing melanoma treatment strategies.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by Guizhou Medical University Ethics Committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

References

1. Lopes F, Sleiman MG, Sebastian K, Bogucka R, Jacobs EA, Adamson AS. UV exposure and the risk of cutaneous melanoma in skin of color: A systematic review. *JAMA Dermatol.* (2021) 157:213–9. doi: 10.1001/jamadermatol.2020.4616

Author contributions

DR: Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Software, Validation, Visualization, Writing – original draft. YS: Data curation, Formal analysis, Visualization, Writing – original draft. DJ:Investigation, Resources, Visualization, Writing – original draft. ZZ: Resources, Visualization, Writing – original draft. YY: Data curation, Investigation, Resources, Writing – original draft. HL: Conceptualization, Investigation, Methodology, Project administration, Validation, Writing – review & editing. DW: Conceptualization, Investigation, Supervision, Validation, Writing – review & editing. YC: Conceptualization, Investigation, Methodology, Project administration, Resources, Validation, Writing – review & editing, Funding acquisition.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by Basic research of Guizhou Cooperational Science Foundation [number ZK (2021) general 466] and Science and Technology Fund of Guizhou Provincial Health Commission [number gzwkj2022-062].

Acknowledgments

All authors acknowledge the contributions from the TCGA project.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

2. Sun L, Guan Z, Wei S, Tan R, Li P, Yan L. Identification of long non-coding and messenger RNAs differentially expressed between primary and metastatic melanoma. *Front Genet.* (2019) 10:292. doi: 10.3389/fgene.2019.00292

3. Wang X, Xiong H, Liang D, Chen Z, Li X, Zhang K. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients. *BMC Cancer*. (2020) 20:378. doi: 10.1186/s12885-020-06849-7

4. Zhang S, Chen K, Zhao Z, Zhang X, Xu L, Liu T, et al. Lower expression of GBP2 associated with less immune cell infiltration and poor prognosis in skin cutaneous melanoma (SKCM). *J Immunother*. (2022) 45:274-83. doi: 10.1097/CJI.00000000000421

5. Xiong J, Chi H, Yang G, Zhao S, Zhang J, Tran LJ, et al. Revolutionizing antitumor therapy: unleashing the potential of B cell-derived exosomes. *Front Immunol.* (2023) 14:1188760. doi: 10.3389/fimmu.2023.1188760

6. Wang J, Zuo Z, Yu Z, Chen Z, Meng X, Ma Z, et al. et al: Single-cell transcriptome analysis revealing the intratumoral heterogeneity of ccRCC and validation of MT2A in pathogenesis. *Funct Integr Genomics*. (2023) 23:300. doi: 10.1007/s10142-023-01225-7

7. Selitsky SR, Mose LE, Smith CC, Chai S, Hoadley KA, Dittmer DP, et al. Prognostic value of B cells in cutaneous melanoma. *Genome Med.* (2019) 11:36. doi: 10.1186/s13073-019-0647-5

8. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. *Nature*. (2015) 527:186–91. doi: 10.1038/nature15726

9. Song G, Peng G, Zhang J, Song B, Yang J, Xie X, et al. Uncovering the potential role of oxidative stress in the development of periodontitis and establishing a stable diagnostic model via combining single-cell and machine learning analysis. *Front Immunol.* (2023) 14:1181467. doi: 10.3389/fimmu.2023.1181467

10. Pilco-Ferreto N, Calaf GM. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. *Int J Oncol.* (2016) 49:753–62. doi: 10.3892/ ijo.2016.3558

11. Hu H, Yang W, Liang Z, Zhou Z, Song Q, Liu W, et al. et al: Amplification of oxidative stress with lycorine and gold-based nanocomposites for synergistic cascade cancer therapy. *J Nanobiotechnology*. (2021) 19:221. doi: 10.1186/s12951-021-00933-1

12. Srivastava AK, Wang Y, Huang R, Skinner C, Thompson T, Pollard L, et al. Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016. *Hum Genomics*. (2016) 10:12. doi: 10.1186/s40246-016-0063-5

13. Zhao S, Chi H, Yang Q, Chen S, Wu C, Lai G, et al. et al: Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease. *Front Immunol.* (2023) 14:1090040. doi: 10.3389/fimmu.2023.1090040

14. Chi H, Yang J, Peng G, Zhang J, Song G, Xie X, et al. Circadian rhythm-related genes index: A predictor for HNSCC prognosis, immunotherapy efficacy, and chemosensitivity. *Front Immunol.* (2023) 14:1091218. doi: 10.3389/fimmu.2023.1091218

15. Zhao S, Zhang X, Gao F, Chi H, Zhang J, Xia Z, et al. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer. *Front Endocrinol (Lausanne)*. (2023) 14:1145797. doi: 10.3389/ fendo.2023.1145797

16. Ren Q, Zhang P, Lin H, Feng Y, Chi H, Zhang X, et al. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts. *Front Immunol.* (2023) 14:1201573. doi: 10.3389/fimmu.2023.1201573

17. Chi H, Zhao S, Yang J, Gao X, Peng G, Zhang J, et al. et al: T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing. *Front Immunol.* (2023) 14:1137025. doi: 10.3389/fimmu.2023.1137025

18. Liu J, Zhang P, Yang F, Jiang K, Sun S, Xia Z, et al. Integrating single-cell analysis and machine learning to create glycosylation-based gene signature for prognostic prediction of uveal melanoma. *Front Endocrinol (Lausanne).* (2023) 14:1163046. doi: 10.3389/fendo.2023.1163046

19. Zhang J, Peng G, Chi H, Yang J, Xie X, Song G, et al. CD8 + T-cell marker genes reveal different immune subtypes of oral lichen planus by integrating single-cell RNA-seq and bulk RNA-sequencing. *BMC Oral Health*. (2023) 23:464. doi: 10.1186/s12903-023-03138-0

20. Zhang P, Pei S, Wu L, Xia Z, Wang Q, Huang X, et al. Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma. *Front Endocrinol (Lausanne).* (2023) 14:1196372. doi: 10.3389/ fendo.2023.1196372

21. Chen X, Jiang X, Wang H, Wang C, Wang C, Pan C, et al. et al: DNA methylation-regulated SNX20 overexpression correlates with poor prognosis, immune cell infiltration, and low-grade glioma progression. *Aging (Albany NY).* (2022) 14:5211–22. doi: 10.18632/aging.v14i12

22. Chi H, Gao X, Xia Z, Yu W, Yin X, Pan Y, et al. et al: FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC. *Front Mol Biosci.* (2023) 10:1200335. doi: 10.3389/fmolb.2023.1200335

23. Zhang X, Zhuge J, Liu J, Xia Z, Wang H, Gao Q, et al. et al: Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma. *Front Immunol.* (2023) 14:1153423. doi: 10.3389/fimmu.2023.1153423

24. Chi H, Xie X, Yan Y, Peng G, Strohmer DF, Lai G, et al. Natural killer cellrelated prognosis signature characterizes immune landscape and predicts prognosis of HNSCC. *Front Immunol.* (2022) 13:1018685. doi: 10.3389/fimmu.2022.1018685 25. Xia Z, Chen S, He M, Li B, Deng Y, Yi L, et al. Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors. *Front Immunol.* (2023) 14:1247178. doi: 10.3389/fimmu.2023.1247178

26. Wang X, Zhao Y, Strohmer DF, Yang W, Xia Z, Yu C. The prognostic value of MicroRNAs associated with fatty acid metabolism in head and neck squamous cell carcinoma. *Front Genet.* (2022) 13:983672. doi: 10.3389/fgene.2022.983672

 Chi H, Jiang P, Xu K, Zhao Y, Song B, Peng G, et al. A novel anoikis-related gene signature predicts prognosis in patients with head and neck squamous cell carcinoma and reveals immune infiltration. *Front Genet.* (2022) 13:984273. doi: 10.3389/ fgene.2022.984273

28. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. *Bioinformatics*. (2004) 20:93–9. doi: 10.1093/bioinformatics/btg382

29. Xiao J, Lin H, Liu B, Xia Z, Zhang J, Jin J. Decreased S1P and SPHK2 are involved in pancreatic acinar cell injury. *biomark Med.* (2019) 13:627–37. doi: 10.2217/bmm-2018-0404

30. Cabrera R, Recule F. Unusual clinical presentations of Malignant melanoma: A review of clinical and histologic features with special emphasis on dermatoscopic findings. *Am J Clin Dermatol.* (2018) 19:15–23. doi: 10.1007/s40257-018-0373-6

31. Yu X, Cong P, Wei W, Zhou Y, Bao Z, Hou H. Construction of prognostic risk model of patients with skin cutaneous melanoma based on TCGA-SKCM methylation cohort. *Comput Math Methods Med.* (2022) 2022:4261329. doi: 10.1155/2022/4261329

32. Han Y, Li X, Yan J, Ma C, Wang X, Pan H, et al. Bioinformatic analysis identifies potential key genes in the pathogenesis of melanoma. *Front Oncol.* (2020) 10:581985. doi: 10.3389/fonc.2020.581985

33. Sheng Z, Han W, Huang B, Shen G. Screening and identification of potential prognostic biomarkers in metastatic skin cutaneous melanoma by bioinformatics analysis. *J Cell Mol Med.* (2020) 24:11613–8. doi: 10.1111/jcmm.15822

34. Muller L, Rietscher K, Keil R, Neuholz M, Hatzfeld M. Plakophilin 3 phosphorylation by ribosomal S6 kinases supports desmosome assembly. *J Cell Sci.* (2020) 133:238295. doi: 10.1242/jcs.238295

35. Dika E, Lambertini M, Venturi F, Veronesi G, Mastroeni S, Hrvatin Stancic B, et al. A comparative demographic study of atypical spitz nevi and Malignant melanoma. *Acta Dermatovenerol Croat.* (2023) 31:165–8.

36. de Vries E, Uribe C, Beltran Rodriguez CC, Caparros A, Meza E, Gil F. Descriptive epidemiology of melanoma diagnosed between 2010 and 2014 in a Colombian cancer registry and a call for improving available data on melanoma in Latin America. *Cancers (Basel).* (2023) 15:5848. doi: 10.3390/cancers15245848

37. Russo D, Dalle S, Dereure O, Mortier L, Dalac-Rat S, Dutriaux C, et al. Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase). *Front Oncol.* (2023) 13:1250026. doi: 10.3389/ fonc.2023.1250026

38. Zhao Y, Wei K, Chi H, Xia Z, Li X. IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines? *Front Immunol.* (2022) 13:1022808. doi: 10.3389/fimmu.2022.1022808

39. Gong X, Chi H, Strohmer DF, Teichmann AT, Xia Z, Wang Q. Exosomes: A potential tool for immunotherapy of ovarian cancer. *Front Immunol.* (2022) 13:1089410. doi: 10.3389/fimmu.2022.1089410

40. Jin W, Yang Q, Chi H, Wei K, Zhang P, Zhao G, et al. Ensemble deep learning enhanced with self-attention for predicting immunotherapeutic responses to cancers. *Front Immunol.* (2022) 13:1025330. doi: 10.3389/fimmu.2022.1025330

41. Xiao J, Huang K, Lin H, Xia Z, Zhang J, Li D, et al. Mogroside II(E) inhibits digestive enzymes via suppression of interleukin 9/interleukin 9 receptor signalling in acute pancreatitis. *Front Pharmacol.* (2020) 11:859. doi: 10.3389/fphar.2020.00859

42. Wang F, Chen S, Liu HB, Parent CA, Coulombe PA. Keratin 6 regulates collective keratinocyte migration by altering cell-cell and cell-matrix adhesion. *J Cell Biol.* (2018) 217:4314–30. doi: 10.1083/jcb.201712130

43. Li M, Zhao J, Yang R, Cai R, Liu X, Xie J, et al. CENPF as an independent prognostic and metastasis biomarker corresponding to CD4+ memory T cells in cutaneous melanoma. *Cancer Sci.* (2022) 113:1220–34. doi: 10.1111/cas.15303

44. Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. *Clin Rev Allergy Immunol.* (2020) 58:313-25. doi: 10.1007/s12016-019-08753-w

45. He Y, Wu S, Yuan Y, Sun Y, Ai Q, Zhou R, et al. Remodeling tumor immunosuppression with molecularly imprinted nanoparticles to enhance immunogenic cell death for cancer immunotherapy. *J Control Release*. (2023) 362:44–57. doi: 10.1016/j.jconrel.2023.08.026

46. Ribatti D, Tamma R, Vacca A. Mast cells and angiogenesis in human plasma cell Malignancies. *Int J Mol Sci.* (2019) 20:481. doi: 10.3390/ijms20030481

47. Xu W, Qian J, Zeng F, Li S, Guo W, Chen L, et al. Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment. *J Exp Clin Cancer Res.* (2019) 38:114. doi: 10.1186/s13046-019-1118-y

48. Sun Z, Wang J, Zhang Q, Meng X, Ma Z, Niu J, et al. et al: Coordinating singlecell and bulk RNA-seq in deciphering the intratumoral immune landscape and prognostic stratification of prostate cancer patients. *Environ Toxicol.* (2024) 39:657– 68. doi: 10.1002/tox.23928 49. Brodehl A, Stanasiuk C, Anselmetti D, Gummert J, Milting H. Incorporation of desmocollin-2 into the plasma membrane requires N-glycosylation at multiple sites. *FEBS Open Bio.* (2019) 9:996–1007. doi: 10.1002/2211-5463.12631

50. Wanuske MT, Brantschen D, Schinner C, Studle C, Walter E, Hiermaier M, et al. Clustering of desmosomal cadherins by desmoplakin is essential for cell-cell adhesion. *Acta Physiol (Oxf)*. (2021) 231:e13609. doi: 10.1111/apha.13609

51. Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. *Blood.* (2019) 133:2159–67. doi: 10.1182/blood-2018-11-844548

52. Masucci MT, Minopoli M, Del Vecchio S, Carriero MV. The emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis. *Front Immunol.* (2020) 11:1749. doi: 10.3389/fimmu.2020.01749

53. Zhang L, Chen C, Chai D, Li C, Qiu Z, Kuang T, et al. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma. *J Transl Med.* (2023) 21:126. doi: 10.1186/s12967-023-03940-y

54. Zhang H, Zhai X, Liu Y, Xia Z, Xia T, Du G, et al. et al: NOP2-mediated m5C Modification of c-Myc in an EIF3A-Dependent Manner to Reprogram Glucose Metabolism and Promote Hepatocellular Carcinoma Progression. *Res (Wash D C)*. (2023) 6:0184. doi: 10.34133/research.0184

55. Gong X, Chi H, Xia Z, Yang G, Tian G. Advances in HPV-associated tumor management: Therapeutic strategies and emerging insights. *J Med Virol.* (2023) 95: e28950. doi: 10.1002/jmv.28950

56. Soltani M, Zhao Y, Xia Z, Ganjalikhani Hakemi M, Bazhin AV. The importance of cellular metabolic pathways in pathogenesis and selective treatments of hematological Malignancies. *Front Oncol.* (2021) 11:767026. doi: 10.3389/ fonc.2021.767026

57. Li Z, Zhou H, Xia Z, Xia T, Du G, Franziska SD, et al. HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma. *biomark Res.* (2023) 11:33. doi: 10.1186/s40364-023-00473-w

58. Zhai X, Xia Z, Du G, Zhang X, Xia T, Ma D, et al. LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance. *Genes Dis.* (2023) 10:2082–96. doi: 10.1016/j.gendis.2022.10.021

59. Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. *Mutat Res Rev Mutat Res.* (2021) 787:108365. doi: 10.1016/j.mrrev.2021.108365

60. Costanzo-Garvey DL, Case AJ, Watson GF, Alsamraae M, Chatterjee A, Oberley-Deegan RE, et al. Prostate cancer addiction to oxidative stress defines sensitivity to anti-tumor neutrophils. *Clin Exp Metastasis.* (2022) 39:641–59. doi: 10.1007/s10585-022-10170-x

61. Batog G, Doloto A, Bak E, Piatkowska-Chmiel I, Krawiec P, Pac-Kozuchowska E, et al. The interplay of oxidative stress and immune dysfunction in Hashimoto's thyroiditis and polycystic ovary syndrome: a comprehensive review. *Front Immunol.* (2023) 14:1211231. doi: 10.3389/fimmu.2023.1211231

62. Dharshini LCP, Rasmi RR, Kathirvelan C, Kumar KM, Saradhadevi KM, Sakthivel KM. Regulatory components of oxidative stress and inflammation and their complex interplay in carcinogenesis. *Appl Biochem Biotechnol.* (2023) 195:2893–916. doi: 10.1007/s12010-022-04266-z

63. Gonzalez MA, Lu DR, Yousefi M, Kroll A, Lo CH, Briseno CG, et al. et al: Phagocytosis increases an oxidative metabolic and immune suppressive signature in tumor macrophages. J Exp Med. (2023) 220:20221472. doi: 10.1084/jem.20221472

64. Wu X, Lu W, Xu C, Jiang C, Zhuo Z, Wang R, et al. et al: macrophages phenotype regulated by IL-6 are associated with the prognosis of platinum-resistant serous ovarian cancer: integrated analysis of clinical trial and omics. *J Immunol Res.* (2023) 2023;6455704. doi: 10.1155/2023/6455704

65. Yang H, Li C, Xie QJCI. Advances in the use of nanomaterials in tumour therapy: challenges and prospects. *Cancer insight* (2023) 2:80–101. doi: 10.58567/ci02010006

66. Yu Y, Wu Y, Zhang Y, Lu M, Su X. Oxidative stress in the tumor microenvironment in gastric cancer and its potential role in immunotherapy. *FEBS Open Bio.* (2023) 13:1238–52. doi: 10.1002/2211-5463.13630

67. Pizzimenti S, Ribero S, Cucci MA, Grattarola M, Monge C, Dianzani C, et al. Oxidative stress-related mechanisms in melanoma and in the acquired resistance to targeted therapies. *Antioxidants (Basel)*. (2021) 10:1942. doi: 10.3390/antiox10121942

68. Yang H, Li Z, Zhu S, Wang W, Zhang J, Zhao D, et al. Molecular mechanisms of pancreatic cancer liver metastasis: the role of PAK2. *Front Immunol.* (2024) 15:1347683. doi: 10.3389/fimmu.2024.1347683

69. Gagliano N, Donne ID, Torri C, Migliori M, Grizzi F, Milzani A, et al. et al: Early cytotoxic effects of ochratoxin A in rat liver: a morphological, biochemical and molecular study. *Toxicology*. (2006) 225:214–24. doi: 10.1016/j.tox.2006.06.004

70. Flemming S, Luissint AC, Kusters DHM, Raya-Sandino A, Fan S, Zhou DW, et al. Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration. *Mol Biol Cell*. (2020) 31:407–18. doi: 10.1091/mbc.E19-12-0692

71. Raya-Sandino A, Luissint AC, Kusters DHM, Narayanan V, Flemming S, Garcia-Hernandez V, et al. Regulation of intestinal epithelial intercellular adhesion and barrier function by desmosomal cadherin desmocollin-2. *Mol Biol Cell*. (2021) 32:753–68. doi: 10.1091/mbc.E20-12-0775

72. Vite A, Gandjbakhch E, Prost C, Fressart V, Fouret P, Neyroud N, et al. Desmosomal cadherins are decreased in explanted arrhythmogenic right ventricular dysplasia/cardiomyopathy patient hearts. *PloS One.* (2013) 8:e75082. doi: 10.1371/journal.pone.0075082

73. Jiang S, Yang X, Lin Y, Liu Y, Tran LJ, Zhang J, et al. Unveiling Anoikis-related genes: A breakthrough in the prognosis of bladder cancer. *J Gene Med.* (2024) 26:e3651. doi: 10.1002/jgm.3651

74. Kurinna S, Schafer M, Ostano P, Karouzakis E, Chiorino G, Bloch W, et al. A novel Nrf2-miR-29-desmocollin-2 axis regulates desmosome function in keratinocytes. *Nat Commun.* (2014) 5:5099. doi: 10.1038/ncomms6099